Drug Trial Radar · NCT07831824
Dose Optimization and Diagnostic Performance in Prostate Cancer (SPARROW [Staging Prostate Cancer With Advanced RM2 Radiotracer Oncologic Workup])
Last checked: Nov 20, 2026Latest source record: Sep 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
408
Planned (sponsor's estimate)
Start
Sep 30, 2026
Primary completion
Sep 30, 2029
Study completion Dec 30, 2029
Sponsor
- Lead sponsor
- Lantheus Medical ImagingIndustry
- Sponsor type
- Industry
- First posted
- Sep 21, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Diagnostic
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, nonrandomized, multicenter study conducted in two sequential parts: an initial Phase 2 Dose Optimization Period followed by the Phase 3 Diagnostic Performance Period. After the optimal administered activity and imaging time window are selected in Phase 2, Phase 3 will enroll participants with recently diagnosed PCa who are at least high risk or have suspected metastatic disease and are eligible for radical prostatectomy with pelvic lymph node dissection (RP+PLND). Safety assessments throughout the study will include monitoring of adverse events, vital signs, ECGs, and clinical laboratory parameters. Participants will be enrolled sequentially in a nonrandomized manner, with competitive enrollment across study sites.
Conditions
- Prostate Cancer
Interventions
[68Ga]-LNTH-2401Drug
\[68Ga\]-LNTH-2401 will be administered to identify newly diagnosed prostate cancer.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 2 Dose Optimization Period: Optimal administered activity (radioactivity) and imaging time window for [68Ga]-LNTH-2401 PET/CT based on image quality and interpretability in participants with either newly diagnosed or BCR PCaTime frame: Day 1
- Phase 2 Dose Optimization Period : Optimal administered activity (radioactivity) and imaging time window for [68Ga]-LNTH-2401 PET/CT based on image quality and interpretability in participants with either newly diagnosed or BCR PCaTime frame: Day 1
- Phase 2 Dose Optimization Period :Biodistribution and radiation dosimetry of [68Ga]-LNTH-2401 in participants with either newly diagnosed or BCR PCa.Time frame: Day 1
- Safety and tolerability of [68Ga] LNTH 2401 in participants with either newly diagnosed or BCR PCa.Time frame: 1 week (Ph2), 6 months (Ph3)
- Safety and tolerability of [68Ga] LNTH 2401 in participants with either newly diagnosed or BCR PCa.Time frame: 1 week (Ph2), 6 months (Ph3)
- Phase 3 Diagnostic Performance Period- Diagnostic accuracy (sensitivity and specificity) of [68Ga]-LNTH-2401 PET/CT imaging for detecting prostate cancer in pelvic lymph nodes, compared to histopathology.Time frame: Enrollment through study completion, average 6 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
BAMF Health
Grand Rapids, Michigan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.